Results 91 to 100 of about 755,873 (344)

The Impact of Cognitive Functioning on Daily Occupations for People with Multiple Sclerosis: A Qualitative Study [PDF]

, 2019
Background: Cognitive rehabilitation research in multiple sclerosis is ever-developing, but the impact of cognitive difficulties, seen in 40% to 80% of people, on daily occupations is not well known.
Hynes, Sinéad M, Mc Auliffe, Aoife
core   +1 more source

High‐Efficacy Treatment in Neuromyelitis Optica Specturm Disorder Patients With Seropositive AQP4 Antibodies—A Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To compare the effectiveness of high‐efficacy treatments (HET) and low‐efficacy treatments (LET) in NMOSD patients with anti‐aquaporin‐4 antibodies (AQP4‐ab). Methods In this multi‐center study, we analyzed 183 AQP4‐ab seropositive NMOSD patients who received immunosuppressive treatments (IST).
Xiang Li, Binbin Xue, Jia Li, Dewei Xie, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Xu Zhang, Junhui Xia, Jie Lin   +10 more
wiley   +1 more source

Whole-Transcriptome Analysis in Peripheral Blood Mononuclear Cells from Patients with Lipid-Specific Oligoclonal IgM Band Characterization Reveals Two Circular RNAs and Two Linear RNAs as Biomarkers of Highly Active Disease

Biomedicines, 2020
The presence of anti-myelin lipid-specific oligoclonal IgM bands (LS-OCMBs) has been defined as an accurate predictor of an aggressive evolution of multiple sclerosis.
Leire Iparraguirre, Danel Olaverri, Telmo Blasco, Lucía Sepúlveda, Tamara Castillo-Triviño, Mercedes Espiño, Lucienne Costa-Frossard, Álvaro Prada, Luisa María Villar, David Otaegui, Maider Muñoz-Culla   +10 more
doaj   +1 more source

Web-based physiotherapy for people affected by multiple sclerosis: a single blind, randomized controlled feasibility study [PDF]

, 2018
Objective: To examine the feasibility of a trial to evaluate web-based physiotherapy compared to a standard home exercise programme in people with multiple sclerosis. Design: Multi-centre, randomized controlled, feasibility study.
Alex McConnachie, Belinda Weller, Berg K, Brazier J, Brennan DM, Cohen J., Curtis L, Elaine H Coulter, Frevel D, Heather Murray, Jennifer Freeman, Khan F, Linda Renfrew, Lorna Paul, Olivia Wu, Paul Mattison, Robert Heggie   +16 more
core   +3 more sources

A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint ...
David G. Lester, Kevin Talbot, Martin R. Turner, Alexander G. Thompson, the Pooled Resource Open‐Access ALS Clinical Trials Consortium   +4 more
wiley   +1 more source

Lifetime exposure to smoking and substance abuse may be associated with late-onset multiple sclerosis: a population-based case-control study

BMC Neurology
Background Late-onset multiple sclerosis (LOMS), defined as the development of MS after the age of 50, has shown a substantial surge in incidence rates and is associated with more rapid progression of disability.
Naghmeh Abbasi Kasbi, Sajjad Ghane Ezabadi, Kosar Kohandel, Faezeh Khodaie, Amir Hossein Sahraian, Sahar Nikkhah Bahrami, Mahsa Mohammadi, Amir Almasi-Hashiani, Sharareh Eskandarieh, Mohammad Ali Sahraian   +9 more
doaj   +1 more source

Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009? [PDF]

, 2019
Background:Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses.
Iezzoni, Lisa I, Kinkel, R Philip, Levin, Jonathan S, Machado, Helene T, Minden, Sarah L, Rosenthal, Meredith B   +5 more
core  

Concurrent TNFRSF1A R92Q and pyrin E230K mutations in a child with multiple sclerosis [PDF]

, 2010
We report a 16-year-old female patient with a severe course of multiple sclerosis and concomitant symptoms suggestive of a hereditary autoinflammatory disease.
Blaschek, Astrid, Borggraefe, I., Heinen, F., Hohlfeld, R., Huss, K., Kümpfel, T., Lohse, P., Mueller-Felber, W.   +7 more
core   +1 more source

Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji, Marcello Moccia, Alessia Bianchi, Charmaine Yam, Weaam Hamed, Suraya Mohamud, Alan J. Thompson, Frederik Barkhof, Ahmed T. Toosy, Olga Ciccarelli   +9 more
wiley   +1 more source

Insights for Healthcare Providers on Shared Decision-Making in Multiple Sclerosis: A Narrative Review

Neurology and Therapy
Shared decision-making (SDM) between the patient and their healthcare provider (HCP) in developing treatment plans is increasingly recognized as central to improving treatment adherence and, ultimately, patient outcomes.
Sharon Stoll, Kathleen Costello, Scott D. Newsome, Hollie Schmidt, Amy B. Sullivan, Barry Hendin   +5 more
doaj   +1 more source